Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole Long-acting Injection in Healthy Subjects and Patients With Schizophrenia
NCT06674694Phase 1Recruiting
- Sponsor
- Sichuan Kelun Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of brexpiprazole long-acting injection in schizophrenia (6 arms), sponsored by Sichuan Kelun Pharmaceutical. Primary endpoints: Number of reported Adverse Events at 90 days, Clinical Laboratory Tests at 90 days and 6 more. Started Apr 2024; status: recruiting.
02
Drugs
brexpiprazole long-acting injection
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06674694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674694.